This study aims to understand the genetic and biochemical makeup of neuroblastic tumors (cancers that start in nerve cells), which can affect how aggressive they are and what treatments might work best. Researchers will analyze your tumor, bone marrow, and blood samples to look at surface markers, genetics, cancer-related genes, and how tumors grow in lab dishes. They will also check your blood and bone marrow for tumor or leukemia cells, and your blood for antibodies that fight tumors. You can join if you have a neuroblastic tumor diagnosed by international standards or if doctors suspect you have one. The study will measure these molecular details and track your health for two years to see how they relate to your outcome. The study is also looking at patients who receive naxitamab as part of their regular care.

Study design

This is an observational study, meaning researchers will collect information without giving any specific treatments. It plans to include up to 2070 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will track your clinical outcome for two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.